Nicox

en fr

About Us
Pipeline, Markets and Science
Investors
News and Events
Contact Us

Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost

October 2, 2019

← Back to blog page

Nicox

Contact Us
Subscribe to news
Legal Notice

Search

© Copyright Nicox, all rights reserved

Cookies

By continuing to use this website, you agree to our Cookie Policy.